Stephen Tomlinson to Disease Models, Animal
This is a "connection" page, showing publications Stephen Tomlinson has written about Disease Models, Animal.
Connection Strength
1.728
-
Thromboembolic Model of Cerebral Ischemia and Reperfusion in Mice. Methods Mol Biol. 2016; 1462:357-72.
Score: 0.300
-
A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration. Invest Ophthalmol Vis Sci. 2009 Jul; 50(7):3056-64.
Score: 0.187
-
Characterization of Novel P-Selectin Targeted Complement Inhibitors in Murine Models of Hindlimb Injury and Transplantation. Front Immunol. 2021; 12:785229.
Score: 0.113
-
Increasing the efficacy and safety of a human complement inhibitor for treating post-transplant cardiac ischemia reperfusion injury by targeting to a graft-specific neoepitope. J Heart Lung Transplant. 2021 10; 40(10):1112-1121.
Score: 0.110
-
Natural immunoglobulin M-based delivery of a complement alternative pathway inhibitor in mouse models of retinal degeneration. Exp Eye Res. 2021 06; 207:108583.
Score: 0.108
-
Targeted complement inhibition salvages stressed neurons and inhibits neuroinflammation after stroke in mice. Sci Transl Med. 2018 05 16; 10(441).
Score: 0.088
-
Regulation of the alternative pathway of complement modulates injury and immunity in a chronic model of dextran sulphate sodium-induced colitis. Clin Exp Immunol. 2015 Mar; 179(3):500-8.
Score: 0.071
-
Dissecting the complement pathway in hepatic injury and regeneration with a novel protective strategy. J Exp Med. 2014 Aug 25; 211(9):1793-805.
Score: 0.068
-
A novel protocol allowing oral delivery of a protein complement inhibitor that subsequently targets to inflamed colon mucosa and ameliorates murine colitis. Clin Exp Immunol. 2014 Aug; 177(2):500-8.
Score: 0.068
-
Complement-dependent injury and protection in a murine model of acute dextran sulfate sodium-induced colitis. J Immunol. 2012 Jun 15; 188(12):6309-18.
Score: 0.058
-
A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer. Blood. 2012 Jun 21; 119(25):6043-51.
Score: 0.058
-
The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice. Arthritis Rheum. 2011 Apr; 63(4):1076-85.
Score: 0.054
-
Complement-dependent inflammation and injury in a murine model of brain dead donor hearts. Circ Res. 2009 Nov 20; 105(11):1094-101.
Score: 0.049
-
A complement C3 inhibitor specifically targeted to sites of complement activation effectively ameliorates collagen-induced arthritis in DBA/1J mice. J Immunol. 2007 Dec 01; 179(11):7860-7.
Score: 0.043
-
Complement inhibitors targeted to the proximal tubule prevent injury in experimental nephrotic syndrome and demonstrate a key role for C5b-9. J Immunol. 2005 May 01; 174(9):5750-7.
Score: 0.036
-
A tumor-expressed inhibitor of the early but not late complement lytic pathway enhances tumor growth in a rat model of human breast cancer. Cancer Res. 2002 Feb 15; 62(4):1110-5.
Score: 0.029
-
Targeting the Complement Alternative Pathway Permits Graft Versus Leukemia Activity while Preventing Graft Versus Host Disease. Clin Cancer Res. 2020 07 01; 26(13):3481-3490.
Score: 0.025
-
Inhibition of the alternative complement pathway accelerates repair processes in the murine model of choroidal neovascularization. Mol Immunol. 2019 04; 108:8-12.
Score: 0.023
-
Complement C3a and C5a receptors promote GVHD by suppressing mitophagy in recipient dendritic cells. JCI Insight. 2018 12 20; 3(24).
Score: 0.023
-
Complement C3-Targeted Gene Therapy Restricts Onset and Progression of Neurodegeneration in Chronic Mouse Glaucoma. Mol Ther. 2018 10 03; 26(10):2379-2396.
Score: 0.023
-
C3a receptor antagonism as a novel therapeutic target for chronic rhinosinusitis. Mucosal Immunol. 2018 09; 11(5):1375-1385.
Score: 0.022
-
A Targeted Inhibitor of the Alternative Complement Pathway Accelerates Recovery From Smoke-Induced Ocular Injury. Invest Ophthalmol Vis Sci. 2016 Apr; 57(4):1728-37.
Score: 0.019
-
Early Application of Auxiliary Partial Orthotopic Liver Transplantation in Murine Model of Wilson Disease. Transplantation. 2015 Nov; 99(11):2317-24.
Score: 0.019
-
Prevention of Defective Placentation and Pregnancy Loss by Blocking Innate Immune Pathways in a Syngeneic Model of Placental Insufficiency. J Immunol. 2015 Aug 01; 195(3):1129-38.
Score: 0.018
-
A new mouse anti-mouse complement receptor type 2 and 1 (CR2/CR1) monoclonal antibody as a tool to study receptor involvement in chronic models of immune responses and disease. Mol Immunol. 2015 Feb; 63(2):479-88.
Score: 0.018
-
The complement regulatory protein CD59: insights into attenuation of choroidal neovascularization. Adv Exp Med Biol. 2014; 801:435-40.
Score: 0.016
-
A new treatment for neurogenic inflammation caused by EV71 with CR2-targeted complement inhibitor. Virol J. 2012 Nov 23; 9:285.
Score: 0.015
-
Targeted inhibition of complement using complement receptor 2-conjugated inhibitors attenuates EAE. Neurosci Lett. 2012 Nov 30; 531(1):35-9.
Score: 0.015
-
Complement and the alternative pathway play an important role in LPS/D-GalN-induced fulminant hepatic failure. PLoS One. 2011; 6(11):e26838.
Score: 0.014
-
Complement inhibition alleviates paraquat-induced acute lung injury. Am J Respir Cell Mol Biol. 2011 Oct; 45(4):834-42.
Score: 0.013
-
Targeted inhibition of complement activation prevents features of preeclampsia in mice. Kidney Int. 2011 Feb; 79(3):331-9.
Score: 0.013
-
A targeted inhibitor of the complement alternative pathway reduces RPE injury and angiogenesis in models of age-related macular degeneration. Adv Exp Med Biol. 2010; 703:137-49.
Score: 0.012